By roping in Prof Rama Velamuri to join the University as the Dean of its School of Management, Mahindra University has affirmed its serious intent. Prof Rama Velamuri has taught Entrepreneurship and Negotiation at China Europe International Business School (CEIBS). He was the Academic Director of CEIBS’s Global Executive MBA. In 2020, CEIBS was ranked #2 globally on the FT’s list of the top EMBA programmes and #5 in the world in its list of top MBA programmes.
Speaking to MBAUniverse.com, Prof Velamuri said, “Yes, I have joined Mahindra University as the Dean of its School of Management on March 1
Everest Medicines Appoints Kevin Guo as Chief Commercial Officer
News provided by
Share this article
Share this article
SHANGHAI, Feb. 18, 2021 /PRNewswire/ Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced today the appointment of Kevin Guo as Chief Commercial Officer. Mr. Guo brings more than 22 years of commercial leadership and business management experience across a number of multinational pharmaceutical companies. Mr. Guo s successful track record of commercial planning and execution for global pharmaceutical companies and his strong cross-cultural leadership skills make him uniquely suited for this important executive position at Everest Medicines, said Kerry Blanchard, MD, PhD, chief executive officer of Everest Medicines. He will play a critical role in ushering Evere
Everest Medicines Appoints Kevin Guo as Chief Commercial Officer prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Haijun Dong to Lead Next Phase of Growth for CRDMO
SAN DIEGO & SHANGHAI–(BUSINESS WIRE)–BioDuro-Sundia, a leading drug discovery and development services organization backed by Advent International, announced today the appointment of Haijun Dong, PhD, MBA as Chief Executive Officer.
Dong will take over from Cyrus K. Mirsaidi, who most recently led the company through its 2020 integration, establishing BioDuro-Sundia as the No. 3 CRDMO in the industry, with more than 2,000 employees and operations in 7 cities across China and the US. The executive team, now led by Dong, will continue to be co-located in both China and the US, providing balance for the global business units that support all aspects of drug discovery, development, and manufacturing both drug substance and drug product.
时间：2021年02月02日 17:41:17 中财网
原标题:粤港湾控股:海外监管公告 发行额外二零二一年到期的14.00%优先票据
IMPORTANT NOTICE
NOT FOR DISTRIBUTION IN THE UNITED STATES
IMPORTANT: You must read the following before continuing. The following applies to the supplemental information circular
following this page, and you are therefore advised to read this carefully before reading, accessing or making any other use of the
supplemental information circular. In accessing the supplemental information circular, you agree to be bound by the following terms
and conditions, including any modifications to them any time you receive any information from us as a result of such access.
NOTHING IN THIS ELECTRONIC TRANSMISSION CONSTITUTES AN OFFER OF SECURITIES FOR SALE IN THE UNITED